Drugs / ORX750
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07096674 | Aug 2025 → Apr 2026 overdue | idiopathic hypersomnia, narcolepsy 1, narcolepsy without cataplexy | Centessa Pharmaceuticals (UK) Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06752668 | Dec 2024 → Dec 2026 expected | idiopathic hypersomnia, narcolepsy 1, narcolepsy without cataplexy | Centessa Pharmaceuticals (UK) Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-09-11 | Nxera Pharma UK Limited | Results Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers nxera.life ↗
Centessa reported that ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency at the first two doses evaluated (1.0 mg and 2.5 mg) in the Maintenance of Wakefulness Test (MWT) compared to placebo. |
| 2024-05-30 | Nxera Pharma UK Limited | Regulatory Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals nxera.life ↗
The milestone was achieved with clearance of the ORX750 Investigational New Drug application and progression of ORX750 into a Phase 1 clinical trial. |
| 2024-05-30 | Nxera Pharma UK Limited | Regulatory Other nxera.life ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-13 | Nxera Pharma UK Limited | Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist nxera.life ↗ |
| 2024-09-11 | Nxera Pharma UK Limited | Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers nxera.life ↗ |
| 2024-05-30 | Nxera Pharma UK Limited | Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals nxera.life ↗ |
| 2024-05-30 | Nxera Pharma UK Limited | Other nxera.life ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORX750 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07096674 ↗ |
| Known as | Cleminorexton | “Cleminorexton (also known as ORX750) is designed to mimic the action of orexin.” NCT06752668 ↗ |
| Action | Activate | “designed to mimic the action of orexin.” NCT06752668 ↗ |
| Route | Oral | “Oral ORX750” NCT07096674 ↗ |